H5N8 vaccine
| Vaccine description | |
|---|---|
| Target | H5N8 |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Zoonotic Influenza Vaccine Seqirus |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status |
|
An H5N8 vaccine is an influenza vaccine intended to provide acquired immunity against H5 subtype influenza A viruses.[1] It is given via Intramuscular injection.[1]
Zoonotic influenza vaccine Seqirus
Zoonotic influenza vaccine Seqirus is authorized for use in the European Union.[1] It contains a flu strain called A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b).[1] Zoonotic influenza vaccine Seqirus was considered to be the best candidate to provide protection against circulating H5 influenza A strains.[1] The most common side effects include reactions at the site of injection (swelling, pain, redness and hardening of the skin), myalgia (muscle pain), headache, tiredness, chills and feeling generally unwell.[1] Zoonotic Influenza Vaccine Seqirus H5N8 is indicated for active immunization against H5 subtype influenza A viruses in adults 18 years of age and older.[1]
Society and culture
The European Commission arranged for a supply of zoonotic influenza vaccine.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Zoonotic Influenza Vaccine Seqirus EPAR". European Medicines Agency (EMA). 9 October 2023. Retrieved 26 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Commission secures access to 665,000 doses of zoonotic influenza vaccines". European Commission (Press release). 11 June 2024. Retrieved 26 September 2024.
